Interleukin‑6 signaling blockade treatment for cytokine release syndrome in COVID‑19 (Review)

  • Chen J
  • Zhang L
  • Hou H
  • et al.
N/ACitations
Citations of this article
66Readers
Mendeley users who have this article in their library.

Abstract

A severe immune response in patients with coronavirus disease 2019 (COVID-19) can cause a potentially lethal unconstrained inflammatory cytokine storm, known as cytokine release syndrome (CRS). The present study provides an overview of the biology underlying CRS and how targeted inhibition of interleukin (IL)-6 signaling may improve outcomes and the survival of patients suffering from COVID-19. Preliminary clinical results have indicated that antagonism of the IL-6 receptor (IL-6R), including with the FDA-approved humanized monoclonal antibody tocilizumab, can improve the outcomes of patients with severe or critical COVID-19 while maintaining a good safety profile. The available clinical data support the expansion of clinical trials using IL-6R targeting inhibitors for severe and critical COVID-19 treatment.

Cite

CITATION STYLE

APA

Chen, J.-J., Zhang, L.-N., Hou, H., Xu, L., & Ji, K. (2020). Interleukin‑6 signaling blockade treatment for cytokine release syndrome in COVID‑19 (Review). Experimental and Therapeutic Medicine, 21(1), 1–1. https://doi.org/10.3892/etm.2020.9456

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free